Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

45 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Thrombotic and bleeding events, mortality, and anticoagulant use among 546,656 hospitalized patients with COVID-19 in the United States: a retrospective cohort study.
Deitelzweig S, Luo X, Nguyen JL, Malhotra D, Emir B, Russ C, Li X, Lee TC, Ferri M, Wiederkehr D, Reimbaeva M, Barnes GD, Piazza G. Deitelzweig S, et al. Among authors: wiederkehr d. J Thromb Thrombolysis. 2022 May;53(4):766-776. doi: 10.1007/s11239-022-02644-2. Epub 2022 Apr 30. J Thromb Thrombolysis. 2022. PMID: 35489004 Free PMC article.
Correction: Thrombotic and bleeding events, mortality, and anticoagulant use among 546,656 hospitalized patients with COVID‑19 in the United States: a retrospective cohort study.
Deitelzweig S, Luo X, Nguyen JL, Malhotra D, Emir B, Russ C, Li X, Lee TC, Ferri M, Wiederkehr D, Reimbaeva M, Barnes GD, Piazza G. Deitelzweig S, et al. Among authors: wiederkehr d. J Thromb Thrombolysis. 2022 Nov;54(4):696. doi: 10.1007/s11239-022-02708-3. Epub 2022 Sep 19. J Thromb Thrombolysis. 2022. PMID: 36121539 Free PMC article. No abstract available.
Estimation of the impact of warfarin's time-in-therapeutic range on stroke and major bleeding rates and its influence on the medical cost avoidance associated with novel oral anticoagulant use-learnings from ARISTOTLE, ROCKET-AF, and RE-LY trials.
Amin A, Deitelzweig S, Jing Y, Makenbaeva D, Wiederkehr D, Lin J, Graham J. Amin A, et al. Among authors: wiederkehr d. J Thromb Thrombolysis. 2014;38(2):150-9. doi: 10.1007/s11239-013-1048-z. J Thromb Thrombolysis. 2014. PMID: 24477787 Review.
Effectiveness and Safety of Apixaban, Low-Molecular-Weight Heparin, and Warfarin among Venous Thromboembolism Patients with Active Cancer: A U.S. Claims Data Analysis.
Cohen A, Keshishian A, Lee T, Wygant G, Rosenblatt L, Hlavacek P, Mardekian J, Wiederkehr D, Sah J, Luo X. Cohen A, et al. Among authors: wiederkehr d. Thromb Haemost. 2021 Mar;121(3):383-395. doi: 10.1055/s-0040-1718728. Epub 2020 Nov 10. Thromb Haemost. 2021. PMID: 33171521 Free PMC article.
Medical costs in the US of clinical events associated with oral anticoagulant (OAC) use compared to warfarin among non-valvular atrial fibrillation patients ≥75 and <75 years of age, based on the ARISTOTLE, RE-LY, and ROCKET-AF trials.
Deitelzweig S, Amin A, Jing Y, Makenbaeva D, Wiederkehr D, Lin J, Graham J. Deitelzweig S, et al. Among authors: wiederkehr d. J Med Econ. 2013 Sep;16(9):1163-8. doi: 10.3111/13696998.2013.826664. Epub 2013 Aug 8. J Med Econ. 2013. PMID: 23869941 Free article.
45 results